Alabama CRS – ACTG Network

Location	Alabama CRS BBRB 256 845 19th Street, S. Birmingham AL 35294
CRS Coordinator	Faye Heard fhoward@uabmc.edu (205)996-4405
CRS Leader	Michael Saag msaag@uab.edu 205-934-7349
Studies	A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5370: Anti-PD-1 Antibody in HIV-1 A5369: p24CE Vaccine Study A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5332: REPRIEVE Trial A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B